CoChat

Restored degradation of the Alzheimer’s amyloid‐β peptide by targeting amyloid formation

Crouch, Peter J., Tew, Deborah J., Du, Tai, Nguyen, Diem Ngoc, Caragounis, Aphrodite, Filiz, Gulay, Blake, Rachel E., Trounce, Ian A., Soon, Cynthia P. W., Laughton, Katrina, Perez, Keyla A., Li, Qiao‐Xin, Cherny, Robert A., Masters, Colin L., Barnham, Kevin J., White, Anthony R. · 2009 · Journal of Neurochemistry
Cited by 88

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Accumulation of neurotoxic amyloid‐β (Aβ) is central to the pathology of Alzheimer’s disease (AD). Elucidating the mechanisms of Aβ accumulation will therefore expedite the development of Aβ‐targeting AD therapeutics. We examined activity of an Aβ‐degrading protease (matrix metalloprotease 2) to investigate whether biochemical factors consistent with conditions in the AD brain contribute to Aβ accumulation by altering Aβ sensitivity to proteolytic degradation. An Aβ amino acid mutation found in familial AD, Aβ interactions with zinc (Zn), and increased Aβ hydrophobicity all strongly prevented Aβ degradation. Consistent to all of these factors is the promotion of specific Aβ aggregates where the protease cleavage site, confirmed by mass spectrometry, is inaccessible within an amyloid structure. These data indicate decreased degradation due to amyloid formation initiates Aβ accumulation by preventing normal protease activity. Zn also prevented Aβ degradation by the proteases neprilysin and insulin degrading enzyme. Treating Zn‐induced Aβ amyloid with the metal‐protein attenuating compound clioquinol reversed amyloid formation and restored the peptide’s sensitivity to degradation by matrix metalloprotease 2. This provides new data indicating that therapeutic compounds designed to modulate Aβ‐metal interactions can inhibit Aβ accumulation by restoring the catalytic potential of Aβ‐degrading proteases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2009.05870.x

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 88

Metadata

Authors
Crouch, P. J., Tew, D. J., Du, T., Nguyen, D. N., Caragounis, A., Filiz, G., Blake, R. E., Trounce, I. A., Soon, C. P. W., Laughton, K., Perez, K. A., Li, Q., Cherny, R. A., Masters, C. L., Barnham, K. J., & White, A. R.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2009-02-09
Volume
108
Issue
5
Pages
1198-1207
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W2087517855
Cited by
88
References
18
FWCI
5.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Restored degradation of the Alzheimer’s amyloid‐β peptide by targeting amyloid formation. https://app.cochat.ai/papers/10.1111/j.1471-4159.2009.05870.x
The paper
Crouch, P. J., Tew, D. J., Du, T., Nguyen, D. N., Caragounis, A., Filiz, G., Blake, R. E., Trounce, I. A., Soon, C. P. W., Laughton, K., Perez, K. A., Li, Q., Cherny, R. A., Masters, C. L., Barnham, K. J., & White, A. R. (2009). Restored degradation of the Alzheimer’s amyloid‐β peptide by targeting amyloid formation. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2009.05870.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.